Moss Adams Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Moss Adams Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.16M	Buy	1,497 +38	+3%	+$29.1K	0.08%	76
2025 Q4	$1.13M	Sell	1,459 -11	-0.7%	-$7.47K	0.08%	74
2025 Q3	$827K	Buy	1,470 +82	+6%	+$46.4K	0.06%	90
2025 Q2	$729K	Buy	1,388 +4	+0.3%	+$2.23K	0.07%	102
2025 Q1	$878K	Buy	1,384 +27	+2%	+$18.6K	0.09%	72
2024 Q4	$967K	Buy	1,357 +923	+213%	+$775K	0.1%	62
2024 Q3	$456K	Buy	434 +15	+4%	+$16.7K	0.05%	100
2024 Q2	$440K	Buy	419 +57	+16%	+$55.3K	0.06%	90
2024 Q1	$348K	Buy	+362	New	+$344K	0.06%	98

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Moss Adams Wealth Advisors's REGN Position: Q1 2026 in Review

Moss Adams Wealth Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 2.6% in Q1 2026, buying an estimated $29.1K and bringing the position to 1,497 shares worth $1.16M. The position accounts for 0.08% of the portfolio, ranked #76.

Moss Adams Wealth Advisors first reported a position in REGN in Q1 2024 and has held it in 9 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Moss Adams Wealth Advisors held 1,497 shares of Regeneron Pharmaceuticals worth $1.16M as of Q1 2026.
Moss Adams Wealth Advisors bought 38 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $29.1K.
Regeneron Pharmaceuticals made up 0.08% of Moss Adams Wealth Advisors's portfolio in Q1 2026, its #76 holding.
Moss Adams Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Moss Adams Wealth Advisors's 13F filing for Q1 2026, filed 23 Apr 2026.